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Carotid intima-media thickness (CIMT) measurements have been used in cardiovascular research for more than
2 decades. There is a wealth of evidence showing that CIMT can be assessed in a reproducible manner and that
increased CIMT relates to unfavorable risk factor levels and atherosclerosis elsewhere in the arterial system and
to the risk of vascular events. Change in CIMT over time can be readily assessed, and trials showed that the rate
of change is modifiable by treatment. Several issues important for the cardiovascular research community and
its application in clinical practice are still outstanding. Promising future areas for CIMT measurements are:
1) application in studies among children and adolescents; 2) use of CIMT trials positioned decisively before the
start of a morbidity and mortality trial; and 3) the use of CIMT measurement in risk stratification in those with
an intermediate 10-year risk estimate. (J Am Coll Cardiol 2012;60:1599–604) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2011.12.061Carotid intima-media thickness (CIMT) measurements
have been applied in cardiovascular (CV) research for more
than 2 decades. There is a wealth of evidence showing that
CIMT can be assessed in a reproducible manner (1), that
increased CIMT relates to unfavorable levels of risk factors
and atherosclerosis elsewhere in the arterial system (2), and
that it shows a consistent and gradual relation to risk of
vascular events (3). Change in CIMT over time can be
readily assessed, and trials have indicated that this rate of
change can be modified by treatment (4–6). Finally, the
American Heart Association has endorsed that measures of
CIMT provide incremental prognostic information over
and above that provided by a traditional risk factor assess-
ment in those with an intermediate risk estimate based on
the Framingham score (7).
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accepted December 17, 2011.The purpose of this report is to address outstanding issues
dealing predominantly with choices of how to measure
CIMT and to point toward promising future areas for
CIMT measurements in research and clinical practice. For
information on technical aspects in the assessment of
CIMT, such as equipment, angles of insonation, electrocar-
diogram triggering, and gain settings, we refer to existing
reviews (8,9).
Measurement Issues
What is CIMT? A characteristic B mode image of the
arterial wall is composed of 2 parallel echogenic lines
separated by a hypoechoic space (Fig. 1). The distance
between the 2 lines reflects the intima-media thickness, a
combined measure of the intima and media layers of the
arterial wall (8). A thickened CIMT measurement does not
lead directly to the occurrence of a myocardial infarction or
stroke. The measurement merely reflects what is going on in
the vasculature of an individual (10). Similarly, the rate of
change in CIMT over time is a reflection of how the
development of atherosclerosis is altered over time. As such,
a CIMT measurement at 1 time point and a measurement
of the rate of change in CIMT over time are both reflections
of CV risk.
Measured CIMT can be used in studies as a primary
outcome or as a risk factor. For example, cohort studies such
as the ARIC (Atherosclerosis Risk In Communities) study
(11,12), the Cardiovascular Health Study (13), and the
Rotterdam Study (14) started with reports dealing with how
risk factors related to CIMT level (CIMT as outcome),
whereas later reports published the relation of CIMT level
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determinant) (11–14). Similarly,
rate of change in CIMT over
time has been used as an out-
come in intervention studies
(5,6,15) and cohort studies
(16,17) as well as a determinant
(rate of change in relation to
events) (18).
Not all CIMTs are the same.
At present there is great diversity
in the choice of ultrasound pro-
tocols used to acquire B-mode ultrasound images from
which CIMT can be measured. The simplest protocol takes
a single image from the far wall of the common carotid in
just 1 of the 2 carotid arteries. The most extensive protocol
is where CIMT images are obtained from both the near and
the far walls of the common carotid artery (CCA), the
carotid bifurcation (BIF or Bulb), and the internal carotid
artery (ICA), at different angles of insonation (from 1 to 5)
and both the left and right carotid artery (19). Thus, at a
single ultrasound visit, one may obtain up to 2  3  5 
2  60 separate images from which CIMT can be mea-
sured. Therefore, there is not 1 “CIMT,” and when evalu-
ating the measure, one must be clear about exactly what
images were incorporated into the measurement.
The most frequently reported CIMT measure is an
average of the far wall of the CCA from both right and left
sides. Studies that collect information beyond the CCA
provide specific CIMT measures for the CCA, BIF (Bulb),
Abbreviations
and Acronyms
BIF  carotid bifurcation
CCA  common carotid
artery
CIMT  carotid intima-
media thickness
CV  cardiovascular
ICA  internal carotid
artery
Figure 1 Characteristic B-Mode Image of Distal Common Carot
Interfaces of the near and far wall carotid intima media thickness from a B-mode ultraand ICA. When CIMT measurements are averaged, some
focus on the average of all measures (mean average), and
some focus on only the maximum values for each segment
(mean maximum). When plaques are present in a segment,
the maximum value is by definition at the maximum height
of the plaque. Thus, mean maximum measures can be
viewed as more heavily weighted toward plaque.
The importance of acknowledging that not all CIMT
measurements are the same comes from the observations
that each specific CIMT has its own specific mean value,
reproducibility, completeness rate during assessment, rate of
change over time, and relation with future CV events
(1,9,20). Finally, for intervention studies, the susceptibility
to drug treatment varies by carotid segment, and it is often
impossible to predict which segment will show the strongest
intervention effect (21,22).
Which CIMT measurement is the best? Clearly, the final
choice for a CIMT measurement depends heavily on your
research question(s) and how the characteristics of that
specific CIMT measurement suit that purpose. We touch
upon several opinions.
What is the best: near versus far wall? In vitro experi-
ments showed that the far wall CIMT most accurately
reflects the true thickness of the wall and that the near wall
is an approximation of the thickness, a fact that is based on
the properties of ultrasound waves (4). Yet, the near wall
CIMT can be measured as reproducibly as the far wall
CIMT and might still carry valuable information that is
specific to the participant under study. In some studies the
combined near and far wall CIMT was the best predictor
tery
image. The dotted vertical line represents the location of the tip of the flow divider.id Ar
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near wall measurements were superior to those having only
the far wall measurements (1,24). This is because greater
precision is achieved when combining the near and far wall,
because of the statistical power of averaging—random error
is reduced when more measures are averaged together (22).
Thus, the “power of averaging” trumps the increased vari-
ability by location. This reasoning applies for near wall
measurements in the CCA, BIF (Bulb), and ICA segments.
Yet, if a single measure of CIMT must be chosen, then the
far wall of the CCA would be the obvious choice.
What is the best: CCA alone versus adding the bifurcation
and internal measurements? Many recommend that clin-
ical measures of CIMT be restricted to the CCA (9). This
is based primarily on issues of reproducibility and availabil-
ity, mainly stemming from CIMT studies that started in the
late 1980s and early 1990s (11–15). However, recent studies
have indicated that CIMT measurement in the bifurcation
and the internal segment can be obtained in over 90% of all
subjects with excellent reproducibility (1,24,25).
When the interest is in relation to events, most reviews
indicate that both CCA alone as well as CCA combined
with ICA measures predict these outcomes to a similar
degree (3,9). When the interest is in the effect of an
intervention, evidence might come from recent trials in
which—on the basis of the CIMT information collected in
the trial—various ultrasound protocols were constructed and
evaluated (1,20,24). The data showed that protocols that
include CIMT measurements at multiple angles of both
near and far wall seem to give the best balance between
reproducibility, rate of CIMT progression, and treatment
effect and their associated precision in these populations.
The CCA segment had results that were superior to the
Bulb and ICA in healthy individuals and familial hypercho-
lesterolemia patients, when results were evaluated by seg-
ment, whereas the 3-segment approach was superior to the
CCA alone in individuals with mixed dyslipidemia and
asymptomatic subclinical atherosclerosis (1,20,24). Al-
though protocols that use extensive image collection might
be considered optimum in trials, there are disadvantages as
well. Extensive ultrasound protocols take more time for
acquisition and quantification and therefore are more costly.
Also, protocols that include measures higher than the CCA
might require more extensive training of sonographers.
Although the data indicate that the more extensive proto-
cols do provide the “best” data, they also indicate that the
less extensive (and thus less expensive) protocols are sensi-
tive enough to measure progression and treatment effect.
Thus, the choice of the exact CIMT protocol to use should
be based on the specific questions that one wants to address
and the resources available. It should be noted that a less
extensive protocol with careful quality control is always
preferable to a more extensive protocol with inadequate
quality control.Quantification of CIMT: manual versus semi-automated
edge detection. Most studies quantify CIMT from ultra-
sound images with a reading program that allows one to
manually draw lines corresponding to the interfaces that
delineate the intima-media thickness or with a semi-
automated edge detection program that assists the reader in
drawing these lines. In the latter case, the software package
uses an edge detection algorithm that allows much of the
reading to be done by computer, with the advantage that
readings are much quicker to perform and the computer is
consistent over time. These programs generally have the
possibility to “override,” because the computer will on
occasion select the wrong pixels for the measurement.
Importantly, it should be noted that, when overriding is a
frequent phenomenon, the benefit of an automated ap-
proach versus a manual one is lost, and reader drift over time
can still occur. In studies comparing a manual approach
with a semi-automated edge detection approach the repro-
ducibility, risk factors relations, rates of change, and treat-
ment effects were similar (26–28). Hence, choices between
semi-automated and manual reading software for CIMT
studies likely should be based on logistical and cost consid-
erations rather than differences in expected data quality
when the choice is made to use far wall common CIMT
measurements.
Promising Future Areas
Use of CIMT measurements in the young. Several as-
pects have made the CIMT measurement very useful to
researchers for application in the young. Noninvasiveness,
absence of ionizing radiation, high reproducibility, and no
apparent side effects are key issues. Also, measures of CIMT
can be combined with measures of vessel diameter to
evaluate the arterial adaptation in response to risk factors.
Landmark studies such as the Cardiovascular Risk in Young
Finns Study, the Childhood Determinants of Adult Health
Study, the Bogalusa Heart Study, the Muscatine Study, and
the Atherosclerosis Risk in Young Adult study showed
consistently that elevated levels of risk factors relate to
increased CIMT (29,30). This was recently expanded by
showing the adverse effects of risk factors (e.g., parental
smoking) on arterial characteristics in children as young as
the age of 5 years (31,32).
Yet, as recently reviewed by Urbina et al. (33), a number
of gaps in our current CIMT knowledge exists that deserves
attention. These include the availability of normative values;
how to account for pubertal stage, body size, and growth;
how CIMT in the young relates to abnormalities of the
vasculature elsewhere; which carotid segments provide the
best information (CCA vs. CCA, BIF, ICA); and cost-
effectiveness of CIMT measures for the identification of
high-risk children.
Use of CIMT measurements in clinical trials. There is
ample evidence that CIMT complies with the set of criteria
that defines a good alternative (surrogate) measure for CV
1602 Bots and Sutton-Tyrrell JACC Vol. 60, No. 17, 2012
CIMT: Promises for the Future October 23, 2012:1599–604disease endpoints as a primary outcome in clinical trials.
These include comparison with a “gold standard”; impres-
sive reproducibility; cross-sectional relations with vascular
risk factors; consistent relations with severity of atheroscle-
rosis elsewhere; relations with future vascular events; and
measurable change over time that is influenced by interven-
tions. One of the final prerequisites for CIMT as a surrogate
endpoint is to show that change in CIMT reflects change in
CV event risk. At present, only 1 published report supports
that notion (34). In addition, 1 recent meta-analysis using
aggregated data supported that notion (35), whereas an-
other did not (36). Unfortunately, both meta-analyses were
considerably flawed (37). These flaws included the pooling
of trials carried out with treatments of heterogeneous
efficacy and in subjects that had very different risk profiles;
the pooling of measurements from a wide variety of meth-
odologies that shared a common name, “CIMT”; a lack of
power for detecting relationships with meta-regression
techniques, and the ecologic fallacy (37). Ongoing studies
will shed light on whether the rate of change in CIMT
achieved either by pharmacological treatment or by natural
history relates to risk of future events (21,38). So far,
however, the evidence for the use of CIMT in clinical trials
is strong and compelling. Almost all lipid level, blood
pressure level, and homocysteine modifying CIMT trials
results were congruent with the corresponding CV event
trials (39,40).
The positioning of CIMT trials in the development
phase of new pharmacological agents deserves attention
(40). Newly developed nonregistered drugs to manage
elevated levels of CV risk factors that arise from phase I and
phase II trials are usually evaluated in M&M (Morbidity
and Mortality) trials, involving thousands of participants
followed over a 3- to 5-year period at a huge cost. Yet,
before embarking on a large M&M trial, an intervention
study testing the efficacy of drug treatment on noninvasively
assessed atherosclerosis progression might be considered
(41). A CIMT trial is done in far fewer participants
(1,000) and might take up to 2 years to complete. Its
results help to support or refute a decision to launch a large
M&M trial, because the results of most of the CIMT trials
are congruent with those found for the M&M trial using
the same compound (39,40). Finally, when the studied
population is a young patient group and a full-blown M&M
trial is not feasible (low incidence of events), one might
want to rely on trials using different modalities to study
change over time in atherosclerosis.
Use of CIMT in risk classification. Although it is clear
that an increased CIMT relates to risk of events, less
evidence is available on how much additional value CIMT
measurement adds to existing risk-assessment methods, like
the Framingham risk score or the Systematic Coronary Risk
Evaluation system (7). At present, the evidence is not
consistent across the studies, which might be attributed to
differences across studies in CIMT measurement, in study
population, in number of events, in cutoff values for riskcategories, and in chosen endpoints (42–48). It seems that
evidence is beginning to emerge in support of the use of
CIMT in risk stratification, particularly for subjects with an
estimated intermediate 10-year CV risk. However, the
current guidelines differ in their recommendations to use
CIMT measurements in primary prevention and also as to
who should be considered, ranging from measurement in all
individuals (49) to measurement in only those at interme-
diate risk (7).
Yet, before widely implementing CIMT measurement in
risk assessment, studies into the cost effectiveness of the
approach are urgently needed. Also, information to substan-
tiate that a CIMT-driven adjustment of preventive ap-
proach indeed results in lower rates of CV events at a
reasonable cost is warranted. Although 2 initiatives to
evaluate this question have been proposed, neither was
funded (50). In the end, the ultimate decision to implement
widespread use of CIMT measurements in risk profiling
depends on the balance between costs and effectiveness (i.e.,
lives saved, events prevented, and quality adjusted life years
gained).
Use of CIMT in the clinical arena. The success of the
CIMT measure in the research arena has fueled a growing
sense that CIMT measures should be adapted for clinical
use in a clinical setting to either screen for or rule out
existing disease, target therapeutic strategies, and evaluate
therapeutic benefit. Although clinical applications are a
logical extension from the research, it requires that we
transition from thinking about the distribution of CIMT
values in a population to the meaning of this measure for an
individual patient. With any new technology, the desire to
adapt the technique for clinical use often begins before there
is definitive evidence of exactly how the technology can best
be used in clinical practice. This creates a gap between the
research and clinical applications for the technology, and
this is where CIMT measures fall now. “Appropriate Use
Criteria” have been suggested as a way to bridge this gap as
a strategy to guide the use of a new technology in the
absence of ideal evidence for judging the appropriateness of
the technology (51).
The development of these criteria takes into account both
the evolving research base as well as the judgment of
clinicians who are faced with the opportunity to use the
technology in clinical practice. These criteria are particularly
important because both market and clinical forces will push
the use of CIMT, regardless of whether or not the research
base is adequate. The development of appropriate use
criteria provides a way to guide the clinical application of
this imaging modality and minimize frivolous or unwar-
ranted use. The Society for Atherosclerosis Imaging and
Prevention in conjunction with the International Athero-
sclerosis Society has taken on the task of developing
appropriate use criteria for CIMT as part of a broader
initiative to shepherd this technology into clinical practice
(52). Briefly, a panel of technical experts was assembled to
review the published data and then rate clinical applications
C
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uses and from current clinical practice guidelines. Each
scenario for CIMT use was scored on a 9-point scale. After
discussion by the full group, a second and final scoring was
done. The clinical indications that were considered appro-
priate (final score of 7 to 9) were primarily for the detection
of CV risk within patients who were at intermediate risk,
had metabolic syndrome, or were older. The rating panel
did not find any clinical scenarios for serial CIMT measures
that were considered appropriate. The goal is to update the
CIMT appropriate use criteria as the published data evolve
so that a combined sense of available medical evidence and
expert clinical judgment can be used to guide the evolution
of clinical use for CIMT (52).
One of the greatest hurdles for the clinical use of CIMT
is a common, recommended protocol that is feasible for a
clinical setting. As discussed in the preceding text, there are
many different CIMT protocols in the research arena. The
choice of which of these would be best for clinical use
depends upon the desired clinical application. One recently
published protocol has components that make it feasible for
many for clinical applications (53). It uses information from
the common, Bulb, and internal carotid segments and
includes a separate measure of focal plaque. The protocol
was shown to be reproducible and was feasible for use in an
office setting, conditional on strict quality control (training,
certification, monitoring), because clinical use of CIMT
cannot go forward without standards to ensure the quality of
both image acquisition and CIMT readings.
Population-based estimates of normative values are an-
other piece necessary to complete the picture for the clinical
use of CIMT. Normative values have been summarized (9).
In general, values from population studies range from
approximately 0.5 mm among young adults to 1.2 mm or
greater among individuals in their 80s. Values are higher
among men than women and are higher among blacks than
whites. However, as discussed previously, it is important to
remember that the distribution of CIMT values varies,
depending on the equipment used, the population studied,
and the exact ultrasound study protocol used. Thus, con-
tinuing to gather and consistently report CIMT values from
population-based studies should be a priority.
As pointed out in the preceding text, rigorous scientific
data are not yet available to support exactly what the best
clinical use of CIMT is.
Summary
CIMT measurements have been available for more than 2
decades. We understand the measurement very well, and
there is a wealth of evidence showing the value of CIMT
measurement in CV disease research. Promising future areas
for these measurements include their use in studies among
children and adolescents, in CIMT trials positioned deci-
sively before the start of an M&M trial, and in risk
stratification.Reprint requests and correspondence: Dr. Michiel L. Bots, Julius
Center for Health Sciences and Primary Care, University Medical
enter Utrecht, Stratenum 6.131, Heidelberglaan 100, 3584
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